These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8356053)

  • 1. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.
    Otto MJ; Garber S; Winslow DL; Reid CD; Aldrich P; Jadhav PK; Patterson CE; Hodge CN; Cheng YS
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7543-7. PubMed ID: 8356053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.
    Partaledis JA; Yamaguchi K; Tisdale M; Blair EE; Falcione C; Maschera B; Myers RE; Pazhanisamy S; Futer O; Cullinan AB
    J Virol; 1995 Sep; 69(9):5228-35. PubMed ID: 7636964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.
    Patick AK; Rose R; Greytok J; Bechtold CM; Hermsmeier MA; Chen PT; Barrish JC; Zahler R; Colonno RJ; Lin PF
    J Virol; 1995 Apr; 69(4):2148-52. PubMed ID: 7884862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A.
    Smidt ML; Potts KE; Tucker SP; Blystone L; Stiebel TR; Stallings WC; McDonald JJ; Pillay D; Richman DD; Bryant ML
    Antimicrob Agents Chemother; 1997 Mar; 41(3):515-22. PubMed ID: 9055985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
    Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.
    Yates PJ; Hazen R; St Clair M; Boone L; Tisdale M; Elston RC
    Antimicrob Agents Chemother; 2006 Mar; 50(3):1092-5. PubMed ID: 16495277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.
    O'Meara D; Wilbe K; Leitner T; Hejdeman B; Albert J; Lundeberg J
    J Clin Microbiol; 2001 Feb; 39(2):464-73. PubMed ID: 11158091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors.
    Maschera B; Furfine E; Blair ED
    J Virol; 1995 Sep; 69(9):5431-6. PubMed ID: 7636988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.
    Kaplan AH; Michael SF; Wehbie RS; Knigge MF; Paul DA; Everitt L; Kempf DJ; Norbeck DW; Erickson JW; Swanstrom R
    Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5597-601. PubMed ID: 8202533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors.
    King RW; Winslow DL; Garber S; Scarnati HT; Bachelor L; Stack S; Otto MJ
    Antiviral Res; 1995 Sep; 28(1):13-24. PubMed ID: 8585757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.
    Jacobsen H; Yasargil K; Winslow DL; Craig JC; Kröhn A; Duncan IB; Mous J
    Virology; 1995 Jan; 206(1):527-34. PubMed ID: 7831807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors.
    Tisdale M; Myers RE; Maschera B; Parry NR; Oliver NM; Blair ED
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1704-10. PubMed ID: 7486905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.
    Kapoor A; Jones M; Shafer RW; Rhee SY; Kazanjian P; Delwart EL
    J Virol; 2004 Jul; 78(13):7112-23. PubMed ID: 15194787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.
    Lech WJ; Wang G; Yang YL; Chee Y; Dorman K; McCrae D; Lazzeroni LC; Erickson JW; Sinsheimer JS; Kaplan AH
    J Virol; 1996 Mar; 70(3):2038-43. PubMed ID: 8627733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.
    Mo H; Markowitz M; Majer P; Burt SK; Gulnik SV; Suvorov LI; Erickson JW; Ho DD
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):55-61. PubMed ID: 8825619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
    Ho DD; Toyoshima T; Mo H; Kempf DJ; Norbeck D; Chen CM; Wideburg NE; Burt SK; Erickson JW; Singh MK
    J Virol; 1994 Mar; 68(3):2016-20. PubMed ID: 8107264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.
    Markowitz M; Mo H; Kempf DJ; Norbeck DW; Bhat TN; Erickson JW; Ho DD
    J Virol; 1995 Feb; 69(2):701-6. PubMed ID: 7815532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.